Trial · NCT03351478
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26 | Sotagliflozin 400 mg | -0.7 | Standard Error 0.1 | percentage of HbA1c | |
| Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26 | Empagliflozin 25 mg | -0.8 | Standard Error 0.1 | percentage of HbA1c | |
| Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26 | Placebo | -0.3 | Standard Error 0.1 | percentage of HbA1c | |
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥ 130 mmHg | Sotagliflozin 400 mg | -5.6 | Standard Error 1.3 | mmHg | |
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥ 130 mmHg | Empagliflozin 25 mg | -6.7 | Standard Error 1.3 | mmHg | |
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥ 130 mmHg | Placebo | -3.5 | Standard Error 1.5 | mmHg | |
| Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26 | Sotagliflozin 400 mg | -1.3 | Standard Error 0.2 | millimole per liter (mmol/L) | |
| Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26 | Empagliflozin 25 mg | -1.2 | Standard Error 0.9 | millimole per liter (mmol/L) | |
| Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26 | Placebo | -0.4 | Standard Error 0.2 | millimole per liter (mmol/L) | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | Sotagliflozin 400 mg | -1.3 | Standard Error 0.2 | mmol/L | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | Empagliflozin 25 mg | -1.6 | Standard Error 0.2 | mmol/L | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | Placebo | -0.5 | Standard Error 0.2 | mmol/L | |
| Change From Baseline in Body Weight at Week 26 | Sotagliflozin 400 mg | -2.7 | Standard Error 0.3 | kilogram (kg) | |
| Change From Baseline in Body Weight at Week 26 | Empagliflozin 25 mg | -3.2 | Standard Error 0.3 | kilogram (kg) | |
| Change From Baseline in Body Weight at Week 26 | Placebo | -0.5 | Standard Error 0.3 | kilogram (kg) | |
| Change From Baseline in Sitting SBP at Week 12 for All Participants | Sotagliflozin 400 mg | -1.7 | Standard Error 0.8 | mmHg | |
| Change From Baseline in Sitting SBP at Week 12 for All Participants | Empagliflozin 25 mg | -2.8 | Standard Error 0.8 | mmHg | |
| Change From Baseline in Sitting SBP at Week 12 for All Participants | Placebo | -0.4 | Standard Error 1.0 | mmHg | |
| Percentage of Participants With HbA1c <6.5% at Week 26 | Sotagliflozin 400 mg | 12.1 | percentage of participants | ||
| Percentage of Participants With HbA1c <6.5% at Week 26 | Empagliflozin 25 mg | 11.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03351478/results